Board & Management

The CSL Board is responsible for oversight of the management of the Company and providing strategic direction.

The Executive Management is responsible for the day to day running of CSL.

---

 

CSL Board Members

Professor John Shine Chairman	Brian McNamee Chief Executive Officer and Managing Director	John Akehurst	David Anstice	Bruce Brook
Christine O'Reilly	Ian Renard	Maurice Renshaw	Paul Perreault Executive Director

---

John Shine, AO

_{BSc (Hon), PhD, DSc, FAA - (Age 66)}

^{Pharmaceutical Industry and Medicine (Resident in NSW)
Independent: Yes}
Chairman
Professor Shine was appointed to the CSL Board in June 2006. He is Professor of Molecular Biology and Professor of Medicine at the University of NSW, and a Director of many scientific research and medical bodies throughout Australia. Professor Shine is President of the Museum of Applied Arts and Science (Powerhouse Museum and Sydney Observatory) and was formerly Executive Director of the Garvan Institute of Medical Research. He was also formerly Chairman of the National Health and Medical Research Council and a Member of the Prime Minister’s Science, Engineering and Innovation Council. In November 2010, he was awarded the 2010 Prime Minister's Prize for Science.


^{Professor Shine is a member of the Innovation and Development Committee.}

---

Brian McNamee, AO

_{MBBS, FAICD, FTSE - (Age 55)}

^{International Pharmaceutical Industry and Medicine (Resident in Victoria)
Independent: No}
Chief Executive Office and Managing Director
Dr McNamee was appointed to the CSL Board in July 1990 and is the Chief Executive Officer and Managing Director. Dr McNamee is a former Director of the Peter MacCallum Cancer Foundation Ltd. Dr McNamee completed Bachelor of Medicine and Bachelor of Surgery Degrees at the University of Melbourne.

^{Dr McNamee is a member of the Innovation and Development Committee.}

---

John Akehurst

_{MA (Oxon), FIMechE - (Age 63)}

^{Engineering and Management (Resident in Western Australia)
Independent: Yes}
Mr Akehurst was appointed to the CSL Board in April 2004. He had 30 years’ executive experience in the international hydrocarbon industry, including seven years as Managing Director and CEO of Woodside Petroleum Ltd. Mr Akehurst is a member of the Board of the Reserve Bank of Australia and is also a Director of Origin Energy Limited, Securency International Pty Ltd and Transform Pty Ltd. He was formerly Chairman of Alinta Limited and of Coogee Resources Limited and is a former Director of Oil Search Limited. Mr Akehurst is Chairman of the National Centre for Asbestos Related Diseases and the Fortitude Foundation and a Director of the University of Western Australia’s Business School. 

^{Mr Akehurst is a member of the Human Resources and Remuneration Committee.}

---

David Anstice

_{BEc - (Age 64)}

^{International Pharmaceutical Industry (Resident in Pennsylvania, USA)
Independent: Yes}
Mr Anstice was appointed to the CSL Board in September 2008. Mr Anstice was a long-time member of the Board of Directors and Executive Committee of the US Biotechnology Industry Organisation, and has over 40 years’ experience in the global pharmaceutical industry. Until August 2008, Mr Anstice was for many years a senior executive of Merck & Co. Inc. serving at various times as President of Merck Human Health for US/Canada/Latin America, Europe, Japan and Asia, and upon retirement was an Executive Vice President. He is a Director of Alkermes Plc, Dublin, Ireland and a Director of the United States Studies Centre at the University of Sydney.

^{Mr Anstice is a member of the Human Resources and Remuneration Committee and the Innovation and Development Committee.}

---

Bruce Brook

_{BCom, BAcc, FCA, MAICD - (Age 57)}

^{Finance and Management (Resident in Victoria)
Independent: Yes}
Mr Brook was appointed to the CSL Board in August 2011. He is currently Chairman of Programmed Maintenance Services Limited and a Director of Boart Longyear Limited and Newmont Mining Corporation. Mr Brook has previously been Chairman of Energy Developments Limited and a Director of Lihir Gold Limited and Consolidated Minerals Limited. During his executive career he was Chief Financial Officer of WMC Resources Limited and prior to that the Deputy Chief Financial Officer of the ANZ Banking Group.

^{Mr Brook is a member of the Audit and Risk Management Committee.}

---

Christine O’Reilly

_{BBus (Age 51)}

^{Finance and Infrastructure (Resident in Victoria)
Independent: Yes}
Ms O’Reilly was appointed to the CSL Board in February 2011. She is a Director of the Transurban Group and Care Australia. During her executive career, she was Co-Head of Unlisted Infrastructure Investments at Colonial First State Global Asset Management and prior to that was the Chief Executive Officer of the GasNet Australia Group.

^{Ms O’Reilly is a member of the Audit and Risk Management Committee and the Human Resources and Remuneration Committee.}

---

Ian Renard, AM

_{BA, LLM, LLD (Hon), FAICD - (Age 66)}

^{Law (Resident in Victoria)
Independent: Yes}
Mr Renard was appointed to the CSL Board in August 1998. For many years he practised in company and commercial law and is a former Chancellor of the University of Melbourne. Mr Renard is a Director of SP AusNet (a listed entity which comprises two companies and a trust), Hillview Quarries Pty Ltd and Peninsula Waste Management Pty Ltd. He is the Chairman of the University of Melbourne Archives Advisory Board and is Chairman of the R E Ross Trust.

^{Mr Renard is Chairman of the Audit and Risk Management Committee.}

---

Maurice Renshaw

_{B.Pharm. - (Age 65)}

^{International Pharmaceutical Industry (Resident in NSW)
Independent: Yes}
Mr Renshaw was appointed to the CSL Board in July 2004. Formerly, he was Vice President of Pfizer Inc, USA, Executive Vice President, Pfizer Global Consumer Group and President of Pfizer’s Global Consumer Healthcare Division. Prior to his positions in Pfizer, Mr Renshaw was Vice President of Warner Lambert Co. and President of Parke-Davis USA. He has had more than 35 years’ experience in the international pharmaceutical industry.

^{Mr Renshaw is Chairman of the Innovation and Development Committee.}

---

Paul Perreault

_{BA Psychology – (Age 55)}


^{International Pharmaceutical Industry (Resident in Pennsylvania, USA)
Independent: No}
Executive Director
Paul joined a CSL predecessor company in 1997. He currently heads CSL Behring as President and works with all areas of the business. Paul’s previous roles were in sales, marketing and operations. He has worked in senior leadership roles with Wyeth, Centeon, Aventis Behring, Aventis Bioservices and CSL. Paul has worked in the health care field for 30 years.

---

Edward Bailey

_{LLB, B.Com, FCIS - (Age 46)}

Company Secretary